The local medical landscape is excited with the introduction of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing impressive results in clinical trials for treating obesity. This therapy https://explorebookmarks.com/story21660244/the-new-retatrutide-australia-a-emerging-hope-for-weight-loss